Immune Control

Immune Control, founded in 2001, operated within the biotechnology and drug discovery sectors from its base in Conshohocken, Pennsylvania. The firm focused on developing a novel class of serotonin-based immunotherapeutics. Its primary business was the creation of orally available, small molecules engineered to modulate the immune system by interacting with serotonin receptors present on immune cells. This mechanism was designed to selectively eliminate activated immune cells, offering a targeted therapeutic approach.

The company's strategic objective was to provide treatments for a range of challenging medical conditions, including autoimmune and inflammatory diseases, hematologic cancers, and the prevention of organ transplant rejection. The core of its therapeutic strategy was to offer a more favorable side effect profile compared to conventional treatments. Immune Control's client base would have consisted of healthcare professionals and their patients in need of these specialized treatments. The business operated as a venture-capital-backed entity, securing funding to advance its research and development pipeline. A significant financial milestone was a Series A funding round on July 13, 2005, which raised $11.3 million, contributing to a total of $17.3 million raised over its lifetime. Key investors included Domain Associates, Anthem Capital Management, NewSpring Capital, and Quaker Partners. The company's trajectory culminated in its acquisition by Corridor Pharmaceuticals on June 17, 2010.

Keywords: immunotherapeutics, serotonin receptors, autoimmune diseases, inflammatory diseases, hematologic cancers, organ transplant rejection, small molecule therapy, drug discovery, biotechnology, selective immune modulation, orally available drugs, venture-backed biotech, Corridor Pharmaceuticals acquisition, Conshohocken biotech, immune system modulation, serotonin-based treatment, activated immune cells, biopharmaceutical research, specialty pharma, targeted therapy, life sciences